title: Life threatening laryngeal toxicity following treatment with combined chemoradiotherapy for nasopharyngeal cancer: a case report with review of the literature.
abstract: Nasopharyngeal carcinoma is a rare cancer in Western society, however there is a higher incidence in Asian. Chinese and African populations. A significant number of Asians reside in Australia, and consequently patients with nasopharyngeal carcinoma are an increasing clinical problem. Radiotherapy has been the predominant treatment in the past, but more recently multi-modality treatments have been utilised. The results of an Intergroup trial, coordinated by the Southwest Oncology Group (SWOG) demonstrated markedly superior progression free and overall survival for combined chemoradiotherapy compared to radiotherapy alone. At three years progression free survival was 24% for the radiotherapy arm and 69% for the chemoradiotherapy group (P < 0.001), and three-year survival was 47% for the radiotherapy arm compared with 78% for the combined arm (P = 0.005). There was minimum toxicity reported for either of the arms and no treatment related deaths. Based on these survival data the administration of concomitant cisplatin and radiotherapy has become standard of care for nasopharyngeal carcinoma in the USA. Our institution has also adopted a similar combined therapy protocol for patients with stage III and IV nasopharyngeal cancer and good performance status. The patients treated at our institution have experienced significant side effects. We describe the case of a woman so treated with this protocol who subsequently developed severe life threatening laryngeal necrosis.
authors.affiliation: Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Baron-Hay
authors.forename: A
authors.initials: A
authors.lastname: Clifford
authors.forename: M
authors.initials: M
authors.lastname: Jackson
authors.forename: S
authors.initials: S
authors.lastname: Clarke
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007830:Larynx / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents